Matching articles for "Capvaxive"

Comparison Table: Pneumococcal Vaccine Recommendations for Adults 19-49 Years Old (online only)

   
The Medical Letter on Drugs and Therapeutics • August 4, 2025;  (Issue 1734)
...
View the Comparison Table: Pneumococcal Vaccine Recommendations for Adults 19-49 Years Old
Med Lett Drugs Ther. 2025 Aug 4;67(1734):e1 | Show Full IntroductionHide Full Introduction

Comparison Table: Pneumococcal Vaccine Recommendations for Adults ≥50 Years Old (online only)

   
The Medical Letter on Drugs and Therapeutics • August 4, 2025;  (Issue 1734)
...
View the Comparison Table: Pneumococcal Vaccine Recommendations for Adults ≥50 Years Old
Med Lett Drugs Ther. 2025 Aug 4;67(1734):e1 | Show Full IntroductionHide Full Introduction

Capvaxive – A 21-Valent Pneumococcal Conjugate Vaccine

   
The Medical Letter on Drugs and Therapeutics • October 14, 2024;  (Issue 1713)
The FDA has licensed Capvaxive (PCV21; Merck), a 21-valent pneumococcal conjugate vaccine, for prevention of invasive pneumococcal disease (IPD) and pneumococcal pneumonia in adults. Four other pneumococcal...
The FDA has licensed Capvaxive (PCV21; Merck), a 21-valent pneumococcal conjugate vaccine, for prevention of invasive pneumococcal disease (IPD) and pneumococcal pneumonia in adults. Four other pneumococcal vaccines are currently available in the US: Prevnar 20 (PCV20), Vaxneuvance (PCV15), and Prevnar 13 (PCV13) are conjugate vaccines licensed for use in persons ≥6 weeks old, and Pneumovax 23 (PPSV23) is a pneumococcal polysaccharide vaccine licensed for use in persons ≥2 years old (see Table 1).
Med Lett Drugs Ther. 2024 Oct 14;66(1713):161-3 | Show Full IntroductionHide Full Introduction